PTC Therapeutics
PTCT
176 hedge funds and large institutions have $2.63B invested in PTC Therapeutics in 2019 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 65 increasing their positions, 57 reducing their positions, and 26 closing their positions.
35% more call options, than puts
Call options by funds: $19.2M | Put options by funds: $14.2M
29% more funds holding in top 10
Funds holding in top 10: 7 → 9 (+2)
19% more capital invested
Capital invested by funds: $2.21B → $2.63B (+$420M)
15% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 26
14% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 57
1% more funds holding
Funds holding: 174 → 176 (+2)
0.46% less ownership
Funds ownership: 100.37% → 99.91% (-0.46%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$28.7M |
| 2 |
Millennium Management
New York
|
+$27.5M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
+$27M |
| 4 |
RI
RTW Investments
New York
|
+$24.6M |
| 5 |
O
OrbiMed
New York
|
+$22.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Scopia Capital Management
New York
|
-$44.4M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$40.9M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$33.7M |
| 4 |
MWNA
Marshall Wace North America
New York
|
-$24.9M |
| 5 |
Renaissance Technologies
New York
|
-$21.3M |
PTCT Hedge Fund Activity: Q2 2019 in Review
176 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in PTC Therapeutics (PTCT) for Q2 2019, worth a combined $2.63B — up 19% from $2.21B a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new PTCT positions and 26 closed out — a net gain of 4 holders — while 65 added to existing stakes and 57 trimmed.
The largest buyer was Pictet Asset Management (UK), adding an estimated $28.7M. The largest seller was Scopia Capital Management, cutting an estimated $44.4M.
- 176 institutional investors held PTC Therapeutics (PTCT) as of Q2 2019, up from 174 in Q1 2019.
- Funds reported $2.63B of PTC Therapeutics stock for Q2 2019, up 19% quarter-over-quarter.
- 30 funds opened new PTC Therapeutics positions in Q2 2019 and 26 closed out, a net change of +4 holders.
- The largest PTC Therapeutics buyer in Q2 2019 was Pictet Asset Management (UK), an estimated $28.7M added.
- The largest PTC Therapeutics seller in Q2 2019 was Scopia Capital Management, an estimated $44.4M sold.
Based on aggregated 13F filings for Q2 2019.